The final moments of the woman's life were captured on security footage. Source: Viral Press/Australscope
The final moments of the woman's life were captured on security footage. Source: Viral Press/Australscope
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.
Edgecore Announces General Availability of new TIP Compliant Entry Level Disaggregated Cell Site Gateway, adding to the Open Mobile Backhaul portfolio
Louvain-la-Neuve, Belgium, 21 January 2021 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update ahead of the Company’s full-year results on March 25, 2021. IBA will report strong results with a positive REBIT and a positive net result for the full year 2020 IBA’s yearly results will be favorably impacted by the EUR 100 million deal signed with CGN Nuclear Technology Development Co., Ltd. (CGNNT) in August. The company has now received the second tranche of EUR 30 million that was due before year-end on the CGNNT agreement, bringing the total received so far to EUR 50 million.IBA notes a FY20 (unaudited) net cash position of EUR 65 million, providing the business with significant stability to progress on its strategic objectives.After a record year in 2019, the Other Accelerators business had a strong 2020 with an order intake of 17 systems. Of these, 12 were signed in the second half, indicating a strong recovery of the market after a slower first half as a result of the COVID-19 pandemic.The Dosimetry business has also been particularly resilient and encouragingly has seen little negative impact from the COVID-19 crisis, with order intake 10% above 2019 In addition, IBA provides the following market update. The Company recently signed a contract with the National Cancer Center (NCC) Korea, for a Proteus®ONE* solution, following a competitive tender process. NCC Korea is already an IBA customer, having purchased a three-room Proteus®PLUS* solution in operation since 2007. The down payment is expected in the coming weeks. IBA has also been selected for the supply of a multi-room Proteus®PLUS solution in China and contract negotiations are ongoing. Olivier Legrain, Chief Executive Officer of IBA SA, said: “The global environment continues to hold many challenges, but I am proud of the resilience shown across all of IBA’s business lines. We had previously identified China and its surrounding regions as being of great strategic importance to the Company and momentum here has continued with discussions ongoing for a multi-room Proteus®PLUS deal in China following on from the significant deal with CGNNT as well as the multi-room Proteus®PLUS order in Sichuan that were both secured during Q3. “There has been an inevitable slow down across other regions, which has impacted installations in the PT and Other Accelerators business overall. On the services side of the business, however, all centers have remained fully operational and have continued to treat patients throughout the crisis, enabling further growth in this revenue line. Looking ahead, order intake in all business units is strong, providing us with visibility for future growth. Importantly, our cash position is stronger than ever, providing us with a solid foundation to continue to innovate whilst further bolstering our resilience.” Shareholder’s AgendaFull Year 2020 Results: 25 March 2021Business Update First Quarter 2021 20 May 2021Half Year 2021 Results 25 August 2021Business Update Third Quarter 2021 18 November 2021 ***Ends*** About IBAIBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are brand names of Proteus 235 For further information, please contact: IBASoumya ChandramouliChief Financial Officer+32 10 475 890Investorrelations@iba-group.com Olivier LechienCorporate Communication Director+32 10 475 firstname.lastname@example.org For media and investor enquiries: Consilium Strategic Communications Amber Fennell, Angela Gray, Lucy Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com Attachment 210121-IBA-FY20-trading_update_ENG
BEIJING, China, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI), an innovator in China’s new energy vehicle market, today announced the safety evaluation results for Li ONE published by the China Insurance Automotive Safety Index (“C-IASI” or “中国保险汽车安全指数”) Management Center based on crash tests. Li ONE achieved the G rating, the highest safety rating, in three out of four evaluation categories – occupant safety, pedestrian safety, and assistance safety. In the category of crashworthiness and repair economy, Li ONE received an M rating, one of the top results received by large premium SUVs. Li ONE’s strong C-IASI performance reflects the Company’s high commitment to vehicle safety. The Company will continue to invest more resources and channel more research and development efforts toward improving the quality and safety of its products in order to provide a safer, more convenient and refined in-car experience and mobility solution. The C-IASI is an assessment and rating program jointly established by China Automotive Engineering Research Institute Co., Ltd. (“中国汽车工程研究院股份有限公司”) and China Insurance Research Institute of Automobile Technology (“中保研汽车技术研究院有限公司”) in 2017. It has become a valued independent auto evaluation system for Chinese consumers while playing a positive role in improving vehicle safety. C-IASI evaluates safety ratings of vehicles based on results from multiple crash tests. The tests for occupant safety include 25% frontal offset impact, side impact, roof strength, and seat and head restraint tests. Both pedestrian headform and legform injury tests are conducted to determine pedestrian safety, while assistance safety is evaluated in the areas of automatic emergency braking (“AEB”), and forward collision warning (“FCW”). For crashworthiness and repair economy, the tests include low speed frontal collision and rear-end collision. The safety ratings use a four-level scale system. The highest rating is G, followed by A, M, and P. About Li Auto Inc. Li Auto Inc. is an innovator in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric SUVs. Through innovative products, technology, and business model, the Company provides customers with safe, convenient, and cost-effective mobility solutions. Li Auto is the first to successfully commercialize extended-range electric vehicles in China. The Company started volume production of its first model, Li ONE, in November 2019. With Li ONE, the Company leverages its in-house technology to create value for its customers, focusing on range extension, smart technology, and autonomous driving solutions. Beyond Li ONE, the Company aims to expand its product line by developing new vehicles to target a broader consumer base. For more information, please visit: http://ir.lixiang.com. Safe Harbor Statement This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto’s strategies, future business development, and financial condition and results of operations; Li Auto’s limited operating history; risks associated with extended-range electric vehicles, Li Auto’s ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto’s ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto’s ability to compete successfully; Li Auto’s ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto’s vehicles; Li Auto’s ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto’s filings with the SEC. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Li Auto Inc.Investor RelationsEmail: email@example.com The Piacente Group, Inc.Yang SongTel: +86-10-6508-0677Email: Li@tpg-ir.com Brandi PiacenteTel: +1-212-481-2050Email: Li@tpg-ir.com
Prosafe SE will release its fourth quarter 2020 results on 4 February 2021 at approx. 07:00 a.m. CET. The Q4 2020 report and the Q4 2020 presentation will be published on www.newsweb.no and on Prosafe’s website www.prosafe.com Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET host an audio webcast. The audio webcast can be followed at www.prosafe.com It will be possible to submit questions during the presentation by using the Q&A tool embedded in the audio webcast. These questions will be answered after the presentation. A replay of the audio webcast will be made available at www.prosafe.com shortly after. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 21 January 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
First patient treated with ADX71149 (JNJ-40411813) scheduled for Q2 2021 Geneva, Switzerland, January 21, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its partner Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has received FDA’s Investigational New Drug (IND) approval to begin a Phase 2a proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with epilepsy. The first patient is expected to be treated during Q2 2021. “IND approval for the mGlu2 epilepsy study is great news to start 2021 and will be the first of three clinical studies we expect to be initiate this year,” said Tim Dyer, CEO of Addex. “There is a great opportunity for an allosteric modulation approach in this difficult disease. We’d like to thank the team involved for their continued support and moving quickly to get this clinical study ready for patient enrolment.” The multi-center study will assess the efficacy, safety, tolerability and pharmacokinetics of adjunctive JNJ-40411813 (ADX71149) administration in patients with focal onset seizures with suboptimal response to levetiracetam. The primary objective of the study is to evaluate the efficacy of JNJ-40411813 (ADX71149) in combination with levetiracetam using a time-to-event endpoint. “There is a strong preclinical rationale for mGlu2 PAM in epilepsy, including a true synergistic effect with levetiracetam,” said Robert Lütjens, Head of Discovery Biology of Addex. "A highly synergistic anti-epileptic effect was observed when the two drugs were administered together, and we look forward to seeing this effect in epilepsy patients.” Glutamate, mGlu2 Receptors and EpilepsyGlutamate is the primary excitatory neurotransmitter in the brain and plays a key role in the initiation and spread of seizures. When activated, the mGlu2 receptor decreases the release of glutamate and consequently helps to maintain neurotransmitter balance. In the presence of agonist-induced activation, positive allosteric modulation of mGlu2 receptors could result in the normalization of the excessive glutamate release seen during a seizure. There is still an urgent need for more effective treatments for epilepsy, with improved tolerability and safety. JNJ-40411813 (ADX71149) was described in the Eilat 15 conference summary review as one of the most promising novel approaches currently in development (Bialer et al., 2019. Epilepsia). Proof of concept data with JNJ-40411813 (ADX71149) and other mGlu2 PAMs in animal models of epilepsy have been published in peer-reviewed journals (Metcalf et al., 2017 and 2018. Epilepsia). About Addex Therapeutics Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in Q2 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and the NASDAQ Capital Market and trades under the ticker symbol "ADXN". Press Contacts: Tim DyerChief Executive OfficerTelephone: +41 22 884 15 55Email: PR@addextherapeutics.comMike SinclairPartner, Halsin Partners+44 (0)20 7318 firstname.lastname@example.org Forward Looking StatementsCertain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo, President: Yasuhiko Saitoh) has developed innovative silicone thermal interface materials for applications in electric vehicles (EV) and hybrid electric vehicles (HEV).
VANCOUVER, British Columbia, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Metallica Metals Corp. (CSE: MM) (OTC: CRUUF) (FWB: SY7P) (the “Company” or “Metallica Metals”) is pleased to announce that it has completed its recent efforts to refocus the Company to exploring and developing precious metals projects in Canada. As previously announced, the Company has acquired several promising mineral projects targeting gold, silver, and palladium and platinum (PGM’s) in some of the most active exploration and mining districts in northern Ontario (Marathon and Thunder Bay Mining Districts). This includes the Starr Project (gold and silver) and Richview Pine and Sammy Ridgeline Projects (palladium and platinum) to complement its existing Big Mac Gold Project in the Golden Triangle region of British Columbia. As part of these efforts, the Company has recently: Completed a name change to better reflect its focus on precious metalsClosed a $300,000 private placementApplied for a new OTC stock tickerRedesigned its corporate website - https://metallica-metals.comUpdated its corporate presentation (now available on website)Opened an office in Toronto to focus on its new gold and PGM projects in OntarioStarted the process of recruiting additional geological talent to its technical team Paul Ténière, CEO and Director of Metallica Metals commented, “The board and management team are excited about finalizing the rebranding of the Company as it refocuses its efforts on exploring and developing gold, silver, and PGM projects in Ontario and BC. We are now turning our attention to planning our exploration activities for summer 2021.” Qualified Person Statement All scientific and technical information contained in this news release was prepared and approved by Paul Ténière, M.Sc., P.Geo., CEO and Director of Metallica Metals Corp., who is a Qualified Person as defined in NI 43-101. On behalf of the Board of Directors METALLICA METALS CORP.Paul Teniere, M.Sc., P.Geo.CEO and DirectorSuite 810 – 789 West Pender StreetVancouver, BC V6C 1H2 Ph: (604) email@example.com For more information, please visit the Company’s website at https://metallica-metals.com or its SEDAR profile at www.sedar.com. Forward-looking Information Statement This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. In particular, forward-looking information in this press release includes, but is not limited to, statements with respect to the Company’s proposed acquisition, exploration program and the expectations for the mining industry. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: general economic conditions in Canada and globally; industry conditions, including governmental regulation and environmental regulation; failure to obtain industry partner and other third party consents and approvals, if and when required; the availability of capital on acceptable terms; the need to obtain required approvals from regulatory authorities; stock market volatility; liabilities inherent in water disposal facility operations; competition for, among other things, skilled personnel and supplies; incorrect assessments of the value of acquisitions; geological, technical, processing and transportation problems; changes in tax laws and incentive programs; failure to realize the anticipated benefits of acquisitions and dispositions; and the other factors. Readers are cautioned that this list of risk factors should not be construed as exhaustive. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Quadient continues reshaping business portfolio with divestment from Graphics activities in Australia and New Zealand § Divestment of Australia and New Zealand Graphics activities to Smartech Business Systems Australia Pty who will also become the distributor of Quadient’s Mail-Related Solutions in the region Paris, 21 January, 2021 Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, today announces the divestment of its Graphics activities in Australia and New Zealand to Smartech Business Systems Australia Pty, a technology solutions provider and a long-term partner working with Quadient in the Asia-Pacific region. As part of the transaction, Smartech Business Systems Australia Pty will become the distributor of Quadient’s Mail-Related Solutions in Australia and New Zealand and will continue to serve Quadient’s more than 19,000 customers in the region. Geoffrey Godet, Chief Executive Officer of Quadient, commented: "The divestment of our Graphics activities and the shift to an indirect distribution model for our Mail-Related Solutions in Australia and New Zealand mark another step forward in the execution of our strategic plan, refocusing our operations and reshaping our portfolio. As part of our ‘Back to Growth’ strategy, we remain fully committed to the development of our strategic solutions in our major geographies while continuing to ‘grow, improve or exit’ our Additional Operations.” Quadient’s operations in Australia and New Zealand employ around 140 people and are part of the Group’s Additional Operations. The transaction was closed on 20 January 2021 and the total selling price amounts to AUD $6 million, including AUD $4 million paid at closing and AUD $2 million deferred payments. As a result of the operation, Quadient will recognize non cash non-current charges of approximately €19 million in the income statement for full-year 2020. *** About Quadient®Quadient is the driving force behind the world’s most meaningful customer experiences. By focusing on four key solution areas including Customer Experience Management, Business Process Automation, Mail-Related Solutions, and Parcel Locker Solutions, Quadient helps simplify the connection between people and what matters. Quadient supports hundreds of thousands of customers worldwide in their quest to create relevant, personalized connections and achieve customer experience excellence. Quadient is listed in compartment B of Euronext Paris (QDT) and is part of the CAC® Mid & Small and EnterNext® Tech 40 indices. For more information about Quadient, visit https://invest.quadient.com/en-US. Contacts Laurent Sfaxi, Quadient+33 (0)1 45 36 61 firstname.lastname@example.org@quadient.comOPRG FinancialIsabelle Laurent / Fabrice Baron+33 (0)1 53 32 61 51 /+33 (0)1 53 32 61 email@example.com firstname.lastname@example.org Caroline Baude, Quadient+33 (0)1 45 36 31 email@example.com Attachment Quadient_Divestment AU_final_EN
With every year, AI is beginning to bring more standardized levels of diagnostic accuracy in medicine. This is true of skin cancer detection, for example, and lung cancers. Now, a startup in Israel called Embryonics says its AI can improve the odds of successfully implanting a healthy embryo during in vitro fertilization.
(Bloomberg) -- One of the world’s fastest vaccine rollouts is fueling one of its best stock rallies.As the United Arab Emirates pushes its inoculation program, the Dubai Financial Market General Index has climbed 12% this year, reversing its 10% slump in 2020. Only two major markets are performing better. MSCI Inc.’s gauge of developing-nation stocks has advanced 8.6%.“Vaccines are a prime reason for this,” said Divye Arora, a money manager at Daman Investments Psc in Dubai. “We have seen a move globally away from growth and defensive toward value and cyclical. Dubai offers both value and cyclical exposure.”The UAE, the third-biggest oil producer in OPEC, has administered more than two million coronavirus vaccine doses, inoculating nearly a fifth of its population, as it tries to emerge from the pandemic. The campaign is seen as key to reviving the economy of Dubai, which is reliant on income from travel and tourism.The second-biggest emirate, Dubai has seen the fastest increase in valuations in the Gulf since March. Its price-earnings ratio based on estimated profits in the next 12 months has jumped to 12.6 times from last year’s low of 4.8. That’s still cheaper than neighboring Abu Dhabi.The decline in the equity risk premium and “strong expected earnings growth starting in the second half of 2021 and through 2022 justifies the multiple expansion,” Arora said. Dubai’s shares lagged behind a broader recovery in emerging markets last year amid concern about the impact of the pandemic on hospitality and aviation.Developing-nation stocks have risen to an all-time high this year, amid a flood of liquidity and optimism over a global economic rebound, surpassing levels last reached before the 2008 global financial crisis.The Dubai gauge rose 1.4% on Wednesday to its highest in almost a year. A sustained rally will depend on the real estate sector, according to Hasnain Malik, the head of equity strategy at Tellimer, who’s based in the city.Yet “on a 12-month view, Dubai shares offer cheap value and tourism is enough to get the market going,” he said.(Updates with Tellimer comments in last two paragraphs.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The launch of 'Hitman 3' has been marred by server problems that prevented players from transferring saves for previous games, or connecting to play the game at all.
South Australian authorities are not ready to lift border restrictions with NSW but have moved to ease some local COVID-19 restrictions.
The man's Mercedes wen up in flames after he floored it while attempting a burnout.
New captain Jake Gordon is bullish about the NSW Waratahs' chances despite their lack of experience for thewSuper Rugby AU season.
(Bloomberg) -- Gold held gains after surging on Wednesday as the dollar extended declines and Joe Biden was sworn in as U.S. president, with investors looking ahead to the potential delivery of more fiscal stimulus. Silver was also in focus after global exchange-traded fund holdings hit an all-time high.Bullion has pushed higher this week as the Bloomberg Dollar Spot Index lost ground each day, while global equities rose to a record. In confirmation hearings, Biden’s Treasury Secretary nominee Janet Yellen said spending was needed to fight the pandemic, while playing down concern over debt levels.“Due to the smooth U.S. transition, investors have become more optimistic that stimulus measures will promote economic recovery and corporate earnings growth,” Huatai Futures Co. said in a report. Inflation expectations have continued to strengthen, and if non-U.S. currencies gain against the dollar, gold will be in a favorable position, the Chinese brokerage said.Spot gold was steady at $1,870.97 at 12:40 p.m. in Singapore, after climbing 1.7% on Wednesday. Silver was 0.2% higher at $25.8876 an ounce, after ETF holdings jumped to 28,312.6 tons, according to an initial Bloomberg tally; that’s the highest figure on record. Platinum fell and palladium rose.On the virus front, Biden plans to re-engage with the World Health Organization and will dispatch the government’s top infectious-disease expert to speak to the group this week. The new president’s team is worried that a more-transmissible strain of the virus threatens his plans to contain the outbreak.Traders are also awaiting the monetary policy decision of the European Central Bank on Thursday. Earlier today, the Bank of Japan left its main policy unchanged after forecasting the economy will regain more lost growth than previously thought once it starts to recover from the current state of emergency. Federal Reserve policy makers hold their inaugural meeting of 2021 next week.The Bloomberg Dollar Spot Index traded 0.2% lower. A fourth day of losses would be the longest losing run since Dec. 17.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The NBA has postponed a sixth consecutive match of the Washington Wizards because of coronavirus protocols.
New US President Joe Biden warned the worst of the pandemic is still to come, as the number of American coronavirus deaths surpassed the country's troop fatalities in World War II.
Tasmania has removed border restrictions for the Greater Brisbane region and much of Sydney, with the premier thanking those in quarantine for their patience.
It's always hard to buy a stock that's trading at an all-time high. In addition, Google's Android operating system has become the standard for the majority of smartphones across the globe, with only Apple's (NASDAQ: AAPL) iOS mounting any considerable challenge to Alphabet's supremacy.